Meeting Impression: SGLT2 Inhibition, Diabetes and CVD

Patients with diabetes have an increased risk for cardiovascular (CV) morbidity and mortality. Great benefit on CV outcome in these patients has been achieved with SGLT-2 inhibitors, which represent the newest class of anti-diabetic medication. During a satellite symposium at the ESC 2016 in Rome, organised by PACE-CME, the impact of CV disease in patients with diabetes, SGLT-2 inhibitor trial outcome data as well as the mechanism by which SGLT-2 inhibitors may affect heart function, were discussed.

Download meeting Impression as PDF